Short Interest in Genfit S.A. (NASDAQ:GNFT) Declines By 6.3%

Genfit S.A. (NASDAQ:GNFT) was the recipient of a large decrease in short interest during the month of December. As of December 15th, there was short interest totalling 59,800 shares, a decrease of 6.3% from the November 30th total of 63,800 shares. Based on an average daily volume of 12,300 shares, the days-to-cover ratio is presently 4.9 days. Currently, 0.1% of the shares of the company are short sold.

Genfit Stock Performance

Shares of GNFT stock opened at $3.71 on Thursday. Genfit has a 1 year low of $3.31 and a 1 year high of $6.42. The firm has a fifty day moving average price of $4.46 and a 200-day moving average price of $4.51. The company has a debt-to-equity ratio of 0.61, a current ratio of 3.74 and a quick ratio of 3.74.

Wall Street Analyst Weigh In

Separately, HC Wainwright restated a “buy” rating and set a $13.00 target price on shares of Genfit in a research report on Friday, October 11th.

About Genfit

Genfit SA, a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis.